Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

340C – Prospective Legislation to Protect Federally Qualified Health Centers

Client Alert
November 14, 2022

Advocates for Community Health (ACH), an organization created to implement policy and advocacy initiatives for health care systems across the United States, has begun drafting legislation that is geared towards protecting Federally Qualified Health Centers (“FQHCs”) enrolled in the 340B Program, which is being dubbed “340C.”

The 340C program would be a separate drug discount program just for FQHCs and perhaps other entities such as rural hospitals and federal grantees like Ryan White Clinics as well. According to ACH: “[o]ur members and leadership came to the decision that health centers and the patients they serve must be protected as reforms to the 340B program are under consideration.”[1] The move seems aimed at distinguishing FQHCs and perhaps other federal grantees from hospitals that currently participate in the 340B program and that have drawn the criticism of some lawmakers.

The main goal of ACH is for funds from the 340B program to be reinvested into FQHCs to fully benefit the patients and communities they serve, as the program was originally intended. However, with 340B reform underway on the federal and state levels, ACH wants to make sure FQHCs are protected; “There is no defensible reason to sweep FQHCs into the ‘reform’ of the 340B program, particularly given that health centers are already required to reinvest any program revenue into patient services.”[2]

In particular, ACH lists three policy recommendations specific to FQHCs:

  • The Centers for Medicare & Medicaid Services (CMS) should update its 2016 outpatient drug rule to clarify that states are permitted to reimburse above actual acquisition cost under fee for service Medicaid for drugs purchased under the 340B program at FQHCs, and provide a federal floor that supersedes state policy.
  • In order to preserve the essential savings provided by the 340B program, CMS and the Health Resources and Services Administration (HRSA) must protect FQHCs against actual acquisition cost and/or forced carve-out policies within Medicaid managed care arrangements.
  • HRSA should establish additional requirements around entity burden reduction before approving manufacturer audits of FQHCs.[3]

When and if the legislation is introduced to Congress, we will update this Alert with more specifics as to what exactly the “340C” Program will entail.

If you have any questions about the 340B Program, please reach out to healthcare attorney, Member Daphne Kackloudis at dlkackloudis@bmdllc.com.

[1] Rita Rey, ACH Stands up to Defend the 340B Program for Health Centers, (Oct. 7, 2022) https://advocatesforcommunityhealth.org/ach-stands-up-to-defend-the-340b-program-for-health-centers/. 

[2] Id.

[3] Advocates for Community Health, “340B Policy Principles & Priorities,” https://advocatesforcommunityhealth.org/policy-advocacy/340b/.

Health LawHealthcare Policy
Client Alert

USCIS Policy Change Impacting Work Authorization: Advisory for Employers and Human Resources

December 8, 2025USCIS has issued a policy memorandum pausing immigration benefit processing for individuals from 19 high-risk countries and requiring a re-review of certain previously approved cases. This change may affect work authorization, employment verification, and workforce stability. Employers and HR teams should review impacted employees and update compliance procedures.Client Alert

CMS Releases CY 2026 Medicare Physician Fee Schedule Final Rule with Key Payment and Telehealth Updates

December 4, 2025CMS issued the CY 2026 Medicare Physician Fee Schedule Final Rule on October 31, 2025, with changes effective January 1, 2026. The Final Rule includes increases to the conversion factor, a new efficiency adjustment, updates to practice expense methodology, permanent telehealth policy changes, revised payment for skin substitutes, expanded rules for Part B drugs and biologicals, enhanced policies for Rural Health Clinics and Federally Qualified Health Centers, and new care management and behavioral health services.Client Alert

Ohio Department of Medicaid Updates: Key Changes to Physician Reimbursement Rates in Early Parenthood

December 3, 2025The Ohio Department of Medicaid has proposed amending Ohio Administrative Code Rule related to covered Medicaid reimbursements for physicians. Beginning on January 1, 2026, they are proposing an increase to rates for prenatal care, childbirth, and infant care and provider visits.Client Alert

Name, Image, and Likeness Agreements in Healthcare

November 14, 2025For example, some healthcare providers have begun to utilize "Name, Image, and Likeness" agreements to promote the brand they have created through their healthcare practice.  We have seen the most healthcare NIL activity with longevity and wellness providers, as well as orthopedics.Client Alert

Compounding GLP-1 Drugs - Recent Updates

November 13, 2025Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.
Older posts